Colgate-Palmolive (India) Q2 FY27 Results: Standalone Net Profit ₹342 Crore on Total Income of ₹1,728 Crore

Earnings
Oral and personal care (FMCG)

Blacklitt Research22 October 20263 min read

Colgate-Palmolive (India) Ltd reported standalone total income of ₹1,727.50 crore and net profit of ₹341.57 crore for the quarter ended 30 Sep 2026. Basic EPS was ₹12.56, and the board declared a First Interim Dividend of ₹24 per share.

Key highlights

Standalone

The company on its own, without its subsidiaries

Total income: ₹1,727.50 crore, up 12.6% YoY and 6.2% QoQ
Net profit and EPS: ₹341.57 crore, up 4.3% YoY and down 0.4% QoQ; basic EPS ₹12.56
Advertising expense: ₹314.82 crore against ₹225.1 crore a year earlier, up 39.9%
First Interim Dividend: ₹24 per equity share, total about ₹653 crore; record date 2 Nov 2026

Summary

Standalone ₹ crore
Particulars	Q2 FY27	Q2 FY26	YoY	Q1 FY27	QoQ
	1,727.50	1,534.53	+12.6%	1,626.10	+6.2%
Revenue from operations	1,705.79	1,519.50	+12.3%	1,603.30	+6.4%
Other income	21.71	15.03	+44.4%	22.80	-4.8%
	341.57	327.51	+4.3%	343.08	-0.4%
Finance costs	0.81	0.99	-18.2%	1.03	-21.4%
Depreciation	34.16	37.19	-8.1%	39.21	-12.9%
Tax expense	118.65	114.77	+3.4%	119.11	-0.4%
Net profit margin	19.77%	21.34%	-1.57 pp	21.10%	-1.33 pp
Tax as share of profit before tax	25.8%	25.9%	-0.17 pp	25.8%	+0.01 pp
EPS, basic (₹)	12.56	12.04	+4.3%	12.61	-0.4%

Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

Growth in total income ran ahead of net profit this quarter. Total income rose 12.6% year on year, while net profit rose 4.3%. Other income rose 44.4% to ₹21.71 crore, which is 1.3% of total income, and revenue from operations rose 12.3%. The press release says net profit after tax excluding one-offs and exceptional items grew 5.5% year on year. It says the one-offs include an inverted duty structure related charge due to GST changes, but the amount of that charge is not stated.

Advertising expense rose to ₹314.82 crore from ₹225.1 crore, up 39.9%, within other expenses. The press release says gross margin expanded 40 bps to 69.6% in Q2, and the CEO says the company expects to deliver robust growth. The filing does not give the reason for the higher advertising spend. Finance costs were ₹0.81 crore against ₹0.99 crore a year earlier, and tax was 25.8% of profit before tax, close to the 25.9% of a year earlier.

Sequentially, net profit was almost flat at ₹341.57 crore against ₹343.08 crore in Q1 FY27. The Q1 figure was after a severance-related exceptional item of ₹3.34 crore, and the quarter under review has no exceptional item, so the two quarters are not affected by it in the same way.

The notes give an exceptional item of ₹3.34 crore for the six months ended 30 Sep 2026, all of it in Q1 FY27, for severance and related expenses from organisational changes. The one-time labour code cost is nil for this quarter. The company has no subsidiary, associate or joint venture, and it reports one primary segment, Personal Care (including Oral Care), without separate segment figures.

The results were reviewed by the statutory auditors, SR BC & Co LLP, who said nothing came to their attention that the statement contains a material misstatement.

Inference

The First Interim Dividend is ₹24 per equity share of Re 1 each for FY 2026-27, which the notes put at ₹652.77 crore in total. The record date is 2 Nov 2026 and payment starts on 19 Nov 2026. The press release gives the total as ₹653 crore.

Management changes are announced in the same filing. Ms. Ragini Gajaria is appointed Internal Auditor from 22 Oct 2026. Mr. Gunjit Jain resigns as Executive Vice President - Marketing effective 30 Nov 2026, and Mr. Akash Parekh is to succeed him from 1 Dec 2026. Mr. Manish Anandani's appointment as Managing Director & CEO needs member approval through a postal ballot, with a cut-off date of 23 Oct 2026. The filing does not say what the amount of the GST-related charge is, how the postal ballot will be decided, or why advertising expense rose.

Reference: Original filing (PDF)

Sign up to continue reading

Create a free account to read the rest of this article and the analysis that follows.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.